Property:Inclusion criteria
This is a property of type Text.
A
Afonseca et al. (2013): Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: A pilot randomized clinical trial +
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, diagnosed with colorectal or gastric cancer and scheduled to receive oxaliplatin-based regimens (fluouracil, leucovarine and oxaliplatin, FLOX; 5-FU/leucovarine plus axaliplatine, FOLFOX; epirubicin, oxaliplatin and capecitabine EOX; and capecitabine plus oxaliplatin, XELOX) +
Akiba et al. (2018): Vitamin D Supplementation and Survival of Patients with Non–small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial +
Histopathologically diagnosed as having NSCLC (adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, or large cell lung carcinoma); with stage IA to IIIA; aged 20 to 75 years at entry; diagnosed and operated at any one of four Jikei University Hospitals at Shimbashi, Kashiwa, Chofu, and Katsushika; with tumor totally resected; discharged without major complications; and could visit the Jikei University Hospitals (Tokyo, Japan) and be followed-up for as long as possible +
Ansari et al. (2016): Efficacy of Ginger in Control of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients Receiving Doxorubicin- Based Chemotherapy +
Patients who were pathologically diagnosed with breast cancer, receiving AC, CAF or TAC chemotherapy regimen, receiving at least 3 chemotherapy cycles +
Arbabi-kalati et al. (2012): Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial +
Chemotherapy treatment by a regimen with the same mucositis probability, including cyclophosphamide, doxorubicin, dacarbazine, gemcitabine, methotrexate, and 5-fluorouracil; Karnofsky performance status 60 or above; life expectancy equal to or more than 6 months; white blood cell (WBC) count equal to or more than 1500cell/ml platelet counts equal to greater than 100000 μL +
Argyriou et al. (2006): A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results +
Adult patients with a confirmed diagnosis of solid or nonmyeloid malignancy scheduled to receive six courses of cumulative DDP-based regimens were enrolled if they had satisfactory liver and renal function, a life expectancy of at least 9 months, and a WHO performance score of 0–1. +
Argyriou et al. (2006): Preventing Paclitaxel-Induced Peripheral neuropathy: A Phase 2 Trial of Vitamin E Supplementation +
Adult patients with a confirmed diagnosis of solid or nonmyeloid malignancy scheduled to receive six courses of paclitaxel-based chemotherapy regimen were enrolled if they had satisfactory liver and renal function, a life expectancy of at least 9 months, and a WHO performance score of 0–1. +
Arslan et al. (2015): Oral Intake of Ginger for Chemotherapy-Induced Nausea and Vomiting Among Women With Breast Cancer +
Female with stage II or III breast cancer, having received previous surgical treatment for breast cancer, currently receiving chemotherapy with adjuvant anthracycline (chemotherapy protocols: anthracycline, cyclophosphamide [Cytoxan®], doxorubicin [Adriamycin®], and 5-fluorouracil [Adrucil®]), receiving palonosetron-aprepitant antiemetic treatment, being at least in the second cycle of chemotherapy, and having experienced chemotherapy-induced nausea with a severity of 3 or higher during the previous cycles +
Asfour et al. (2006): Effect of high-dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis in non-Hodgkin's lymphoma patients +
Newly diagnosed non-Hodgkin’s lymphoma (NHL) of intermediate and high grade +
Attia et al. (2008): Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer +
≥18 years of age, histologic diagnosis of prostate adenocarcinoma, radiographic evidence of metastasis, chemotherapy naive (although immunotherapy and experimental therapies were allowed if given ≥4 week before), Eastern Cooperative Oncology Group performance status of ≤2, life expectancy of ≥3 month, and written informed consent; adequate major organ function (WBC count ≥3,000/μL, absolute neutrophil count >1,500/μL, platelet count ≥100,000/μL, hemoglobin ≥10 g/dL, total bilirubin below the institutional upper limit of normal, creatinine ≤1.8 mg/dL, alanine and aspartate transaminases <2.5 times the upper limit of normal, serum calcium ≤10.2 mg/dL, and serum phosphorus ≤5.0 mg/dL));
discontinuation, at least 4 week before, of PC-SPES, saw palmetto, or other herbal supplements used as treatment for prostate cancer; peripheral neuropathy grade ≤1; and prior treatment with bilateral orchiectomy or other primary hormonal therapy with subsequent treatment failure +
Azizi et al. (2015): Efficacy of Topical and Systemic Vitamin E in Preventing Chemotherapy-induced Oral Mucositis +
At least 18 years of age, diagnosis of a hematologic cancer (leukemia or lymphoma), and non-smoker and non-alcoholic. +
B
Bairati et al. (2005): A Randomized Trial of Antioxidant Vitamins to Prevent Second Primary Cancers in Head and Neck Cancer Patients +
- First diagnosis of stage I or II, histologically documented, squamous cell carcinoma of the tongue, gum, mouth, oropharynx, hypopharynx, pharynx, or larynx
- scheduled to be treated by radiation therapy between October 1, 1994, and June 6, 2000, in one of five radiation therapy centers in the province of Quebec, Canada +
Bairati et al. (2005): Randomized Trial of Antioxidant Vitamins to Prevent Acute Adverse Effects of Radiation Therapy in Head and Neck Cancer Patients +
- First diagnosis of stage I or II, histologically documented, squamous cell carcinoma of the tongue, gum, mouth, oropharynx, hypopharynx, pharynx, or larynx
- scheduled to be treated by radiation therapy between October 1, 1994, and June 6, 2000, in one of five radiation therapy centers in the province of Quebec, Canada +
Bairati et al. (2006): Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients +
- First diagnosis of stage I or II, histologically documented, squamous cell carcinoma of the tongue, gum, mouth, oropharynx, hypopharynx, pharynx, or larynx
- scheduled to be treated by radiation therapy between October 1, 1994, and June 6, 2000, in one of five radiation therapy centers in the province of Quebec, Canada +
Barton et al. (1998): Prospective evaluation of vitamin E for hot flashes in breast cancer survivors +
Must have had hot flashes for at least 1 month with a frequency of at least 14 times per week. Women had to have a life expectancy of 6 months or more and a performance status of O or 1 on the Eastern Cooperative Oncology Group scale; use of the antiestrogen tamoxifen was allowed +
Barton et al. (2013): The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9 +
Newly diagnosed; chemotherapy; chemo-naive +
Beer et al. (2007): Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators +
Men with histopathologically or cytologically proven metastatic adenocarcinoma of the prostate with evidence of progression (the development of new metastatic lesions or rising PSA) despite standard hormonal management (orchiectomy, gonadotropin-releasing hormone agonist or antagonist including withdrawal of antiandrogens, if applicable; 6 weeks for bicalutamide, 4 weeks for flutamide or nilutamide) were eligible;
serum PSA ≥ 5.0 ng/mL, serum testosterone level ≤ 50 ng/dL, Eastern Cooperative Oncology Group performance status ≤ 2, life expectancy ≥ 3 months, age ≥ 18 years, patient agreement to use adequate contraception, and patient ability to give informed consent. +
Bossi et al. (2017): A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin +
Adult (>18years) patients of either gender with solid tumors and chemotherapy-naive who were planned to receive more than 2 cycles of HEC with cisplatin (single dose >50 mg/m2 every 21 or 28 days) +
Braga et al. (2015): Effect of Zinc Supplementation on Serological Response to Vaccination Against Streptococcus Pneumoniae in Patients Undergoing Chemotherapy for Colorectal Cancer +
Surgery for Stage II, III, or IV colon or rectum/sigmoid colon cancer; indication of chemotherapy +
Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy +
Cancer requiring capecitabine therapy; never received capecitabine before; performance status of 0 to 2, according to the Eastern Cooperative Oncology Group (ECOG) classifcation; ife expectancy longer than 6 months; not being on vitamin B supplements; no prior HFS; no contraindication to chemotherapy (ie, patient had adequate bone marrow function, including an absolute neutrophil count > 1,500 cells/L and a platelet count > 100,000/L); adequate renal function (as indicated by a serum creatinine concentration < 1.5 mg/dL); adequate liver function (as indicated by a serum bilirubin concentration < 1.5 mg/dL, a transaminase level < 3 times the upper normal limit, and a serum albumin level > 2.5 mg/dL) +